Thilo Schroeder - Mar 17, 2022 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role: Director
Signature: /s/ Darren DeStefano, Attorney-in-Fact
Stock symbol: RVMD
Transactions as of: Mar 17, 2022
Transactions value $: $3,429,033
Form type: 4
Date filed: 3/21/2022, 09:24 PM
Previous filing: Mar 14, 2022
Next filing: Mar 24, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RVMD	Common Stock	Purchase	$190K	+10.1K	+1.92%	$18.78	538K	Mar 17, 2022	By Nextech Crossover I SCSP	F1, F2
transaction	RVMD	Common Stock	Purchase	$116K	+5.99K	+1.11%	$19.28	544K	Mar 18, 2022	By Nextech Crossover I SCSP	F2, F3
transaction	RVMD	Common Stock	Purchase	$1.55M	+76.2K	+14%	$20.38	620K	Mar 18, 2022	By Nextech Crossover I SCSP	F2, F4
transaction	RVMD	Common Stock	Purchase	$1.55M	+74.9K	+12.06%	$20.73	695K	Mar 21, 2022	By Nextech Crossover I SCSP	F2, F5
transaction	RVMD	Common Stock	Purchase	$18.7K	+879	+0.13%	$21.22	696K	Mar 21, 2022	By Nextech Crossover I SCSP	F2, F6
holding	RVMD	Common Stock						2.67M	Mar 17, 2022	By Nextech V Oncology S.C.S., SICAV-SIF	F7
holding	RVMD	Common Stock						300K	Mar 17, 2022	By Nextech VI Oncology SCSp	F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.37 to $19.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.77 to $19.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.78 to $20.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F5	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.21 to $21.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F6	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.21 to $21.23 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F7	Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F8	Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.